Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Race Oncology Ltd. ( (AU:RAC) ) has shared an announcement.
Race Oncology Ltd has made a significant breakthrough in the composition of matter intellectual property with the discovery that bisantrene consists of three photoisomers with varying anticancer activities. The company has filed three patent applications to protect the active (E,E)-bisantrene isomer, which could provide 20 years of intellectual property protection, enhancing Race’s commercial prospects and strengthening its position in pharmaceutical partnering discussions.
More about Race Oncology Ltd.
Race Oncology Ltd is a pharmaceutical company focused on the discovery and development of cancer therapies. The company specializes in the research of bisantrene, a compound with anticancer properties, and is committed to advancing its formulations and intellectual property in the pharmaceutical industry.
Average Trading Volume: 127,231
Technical Sentiment Signal: Buy
Current Market Cap: A$279.8M
For an in-depth examination of RAC stock, go to TipRanks’ Overview page.